BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32213206)

  • 1. Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.
    Vidal M; Delgado A; Martinez C; Correa JJ; Durango IC
    Int Braz J Urol; 2020; 46(4):599-611. PubMed ID: 32213206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic biomarkers in the use of radium-223 in patients with metastatic castration-resistent prostate cancer.
    Vidal M; Cárdenas-Perilla R; Delgado A; Morón S; Londoño Blair JL; Vega I; Correa Ochoa JJ; Rojas J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(5):310-318. PubMed ID: 37419250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
    Serretta V; Valerio MR; Costa R; Tripoli V; Murabito A; Princiotta A; Scalici Gesolfo C; Borsellino N; Verderame F; Gebbia V; Licari M; Sanfilippo C;
    Urol Oncol; 2019 Dec; 37(12):964-969. PubMed ID: 31601517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing Radiographic Response to
    Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
    J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.
    Etchebehere EC; Milton DR; Araujo JC; Swanston NM; Macapinlac HA; Rohren EM
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):8-20. PubMed ID: 26416392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
    van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullén A
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3325-3334. PubMed ID: 33686456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
    Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
    Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.
    Hyväkkä A; Kääriäinen OS; Utriainen T; Löyttyniemi E; Mattila K; Reinikainen P; Sormunen J; Jääskeläinen M; Auvinen P; Minn H; Sundvall M
    Cancer Med; 2023 Feb; 12(4):4064-4076. PubMed ID: 36156455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice.
    van der Doelen MJ; Kuppen MCP; Jonker MA; Mehra N; Janssen MJR; van Oort IM; Gerritsen WR
    Clin Nucl Med; 2018 Jan; 43(1):9-16. PubMed ID: 29166331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with
    Frantellizzi V; Farcomeni A; Follacchio GA; Pacilio M; Pellegrini R; Pani R; De Vincentis G
    Ann Nucl Med; 2018 Feb; 32(2):142-148. PubMed ID: 29285670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region.
    Maruzzo M; Basso U; Borsatti E; Evangelista L; Alongi F; Caffo O; Maines F; Galuppo S; De Vivo R; Zustovich F; Palleschi D; Zivi A; Sava T; Sorarù M; Iacovelli R; Nicodemo M; Baier S; Fratino L; Zagonel V
    Clin Genitourin Cancer; 2019 Feb; 17(1):e187-e194. PubMed ID: 30448106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
    Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of Palliative
    Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T
    J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.
    Caffo O; Frantellizzi V; Tucci M; Galli L; Monari F; Baldari S; Masini C; Bortolus R; Facchini G; Alongi P; Agostini S; Zichi C; Biasco E; Fanti S; Pignata S; Filice A; Borsatti E; Rossetti S; Spada M; Cortesi E; De Vincentis G
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2633-2638. PubMed ID: 32249345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
    Al-Ezzi EM; Alqaisi HA; Iafolla MAJ; Wang L; Sridhar SS; Sacher AG; Fallah-Rad N; Jiang DM; Watson GA; Catton CN; Warde PR; Hamilton RJ; Fleshner NE; Zlotta AR; Hansen AR
    Cancer Med; 2021 Sep; 10(17):5775-5782. PubMed ID: 34254464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
    Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
    Bauckneht M; Rebuzzi SE; Signori A; Frantellizzi V; Murianni V; Lodi Rizzini E; Mascia M; Lavelli V; Donegani MI; Ponzano M; Gaudiano A; Stazza ML; Licari M; Cavallini L; Laghi V; Cindolo L; Maggi M; Sciarra A; Mammucci P; Sambuceti G; Costa RP; Spanu A; Rubini G; Monari F; De Vincentis G; Fornarini G
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1063-1074. PubMed ID: 34486070
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
    J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study.
    Frantellizzi V; Monari F; Mascia M; Costa R; Rubini G; Spanu A; Farcomeni A; Lodi Rizzini E; Cindolo L; Licari M; Lavelli V; Nuvoli S; Ricci M; Dionisi V; Nappi AG; De Vincentis G
    Int J Radiat Biol; 2020 Dec; 96(12):1608-1613. PubMed ID: 33074066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.